

ASX Announcement and Media Release

17 March 2004

SciGen Limited

Entry of SciTropin™ into Indian market.

SciGen Limited (“SciGen”) today announced that it had received health registration approval for its recombinant human growth hormone (SciTropin™) in India.

Chief Executive Officer and Managing Director, Mark Compton said, “This is a very significant milestone for the company as it now provides for sales of SciTropin™ through our commercial partners in India. To date, SciTropin™ has been the lead product for SciGen and the key to the company’s revenue growth over the last 18 months. Our expectation is that SciTropin™ will perform well in the large and expanding Indian pharmaceutical market”.

“This approval is significant as it is the first approval for the Company in India, and demonstrates the company’s standing with the Indian Health Authorities and paves the way for future product registrations in that country”, Mr Compton said.

SciTropin™ has uses across the World in the treatment of short stature in children due to human growth hormone deficiency; Turner’s syndrome; adult growth hormone deficiency and in a range of other clinical conditions for which growth hormone is being found to have significant benefit such as in longevity medicine.

Human growth hormone is one of the oldest pharmaceuticals made using recombinant DNA technology and has been used safely and effectively for many years. New uses for growth hormone see expanding global markets for this product.

SciGen has exclusive rights for SciTropin™ in the Asia Pacific region (including India and China).

It is expected that sales will commence prior to the end of this financial year.

SciGen’s recombinant human insulin is expected to be registered in India in the very near future and the registration process of its 3rd generation hepatitis B vaccine- Sci-B-Vac™ in India is well underway.

About SciGen

SciGen Ltd is a progressive biotechnology/biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singaporean biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has offices in Australia, USA, Korea, Vietnam, Hong Kong and Philippines and partners in India, Indonesia, Israel, Poland and the Netherlands.

=====ENDS=====

Media enquiries

Mark Compton

Managing Director & CEO

Telephone: +61 2 9234 1700

Web: www.scigen.com.au